2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Hea

{"article_title":"In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and\/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, (EHRA), (EAPCI), and (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).","author":"Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K","journal_title":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","issn":"1532-2092","isbn":"","publication_date":"2018 Aug 06","volume":"21","issue":"2","first_page":"192","page_count":"","accession_number":"30052888","doi":"10.1093\/europace\/euy174","publisher":"Oxford University Press","doctype":"Journal Article","subjects":"Acute Coronary Syndrome therapy; Anticoagulants therapeutic use; Atrial Fibrillation drug therapy; Cardiac Catheterization adverse effects; Fibrinolytic Agents therapeutic use; Heart Valve Diseases therapy; Percutaneous Coronary Intervention adverse effects; Platelet Aggregation Inhibitors therapeutic use; Stroke prevention & control; Acute Coronary Syndrome diagnosis; Acute Coronary Syndrome epidemiology; Anticoagulants adverse effects; Atrial Fibrillation diagnosis; Atrial Fibrillation epidemiology; Consensus; Fibrinolytic Agents adverse effects; Heart Valve Diseases diagnosis; Heart Valve Diseases epidemiology; Hemorrhage chemically induced; Humans; Platelet Aggregation Inhibitors adverse effects; Risk Assessment; Risk Factors; Stroke diagnosis; Stroke epidemiology; Treatment Outcome","interest_area":["Hematology"," Cardiology"," Emergency Medicine"],"abstract":"In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and\/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices\/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and\/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=30052888&authtype=shib&custid=ns346513&group=main&profile=eds","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K","Corporate_Authors":"ESC Scientific Document Group","Journal_Info":"Publisher: Oxford University Press Country of Publication: England NLM ID: 100883649 Publication Model: Print Cited Medium: Internet ISSN: 1532-2092 (Electronic) Linking ISSN: 10995129 NLM ISO Abbreviation: Europace Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline; Review","Published_Date":"2019-02-01","Source":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology [Europace] 2019 Feb 01; Vol. 21 (2), pp. 192-193.","Languages":"English","Electronic_ISSN":"1532-2092","MeSH_Terms":"Cardiac Catheterization*\/adverse effects , Percutaneous Coronary Intervention*\/adverse effects, Acute Coronary Syndrome\/*therapy , Anticoagulants\/*therapeutic use , Atrial Fibrillation\/*drug therapy , Fibrinolytic Agents\/*therapeutic use , Heart Valve Diseases\/*therapy , Platelet Aggregation Inhibitors\/*therapeutic use , Stroke\/*prevention & control, Acute Coronary Syndrome\/diagnosis ; Acute Coronary Syndrome\/epidemiology ; Anticoagulants\/adverse effects ; Atrial Fibrillation\/diagnosis ; Atrial Fibrillation\/epidemiology ; Consensus ; Fibrinolytic Agents\/adverse effects ; Heart Valve Diseases\/diagnosis ; Heart Valve Diseases\/epidemiology ; Hemorrhage\/chemically induced ; Humans ; Platelet Aggregation Inhibitors\/adverse effects ; Risk Assessment ; Risk Factors ; Stroke\/diagnosis ; Stroke\/epidemiology ; Treatment Outcome","Subjects":"Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome epidemiology, Anticoagulants adverse effects, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Consensus, Fibrinolytic Agents adverse effects, Heart Valve Diseases diagnosis, Heart Valve Diseases epidemiology, Hemorrhage chemically induced, Humans, Platelet Aggregation Inhibitors adverse effects, Risk Assessment, Risk Factors, Stroke diagnosis, Stroke epidemiology, Treatment Outcome, Acute Coronary Syndrome therapy, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Cardiac Catheterization adverse effects, Fibrinolytic Agents therapeutic use, Heart Valve Diseases therapy, Percutaneous Coronary Intervention adverse effects, Platelet Aggregation Inhibitors therapeutic use, Stroke prevention & control","Title_Abbreviations":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","Volume":"21"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"30052888","RelevancyScore":"822","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"822.270751953125"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=30052888&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=30052888&authtype=shib&custid=ns346513&group=main&profile=eds"}